enGene Holdings

enGene Holdings Inc. is developing a proprietary Dually Derivatized Oligochitosan® (DDX®) non-viral gene-delivery platform designed to administer therapeutic genetic payloads directly to mucosal surfaces and organs. Its lead program targets non-muscle invasive bladder cancer (NMIBC) and the company is advancing toward broader therapeutic applications leveraging the same platform. enGene focuses on execution of clinical milestones, regulatory engagement, and strategic collaborations to scale its pipeline and platform capabilities.